CJC-1295 + Ipamorelin Injection Peptides Support Plan

OVERVIEW:

This treatment plan outlines the dosage, administration, expected benefits, and potential side effects of CJC-1295 + Ipamorelin, a combination peptide therapy. Please read this plan carefully, along with the information provided with your medication, for complete details regarding precautions, handling, and other important safety information.

CJC-1295 + Ipamorelin therapy is considered investigational and is typically used as part of a broader regenerative or longevity-focused treatment plan.

INSTRUCTIONS:

For regenerative support, you have been prescribed:

CJC-1295 + Ipamorelin (9 mg / 15 mg in 6 mL vial)

Dosing:

  • Inject 200 mcg daily
  • 25 doses total (25-day course)

General guidance:

  • Administer via subcutaneous injection (under the skin) unless otherwise directed
  • Use a new sterile needle and syringe for each injection
  • Rotate injection sites (commonly abdomen or thigh)
  • Use the exact prescribed dose and schedule
  • Do not exceed the recommended dose
  • Store medication as directed (commonly refrigerated after reconstitution)
  • Do not use if the solution appears cloudy or contains particles

Your provider may adjust dosing or duration based on your response and treatment goals.

IMPORTANT NOTES REGARDING YOUR TREATMENT:

Use only as prescribed. Do not increase your dose or frequency without provider guidance.

CJC-1295 + Ipamorelin is considered investigational and is not FDA-approved for the treatment of specific medical conditions.

Possible side effects may include injection site irritation, mild water retention, headache, or flushing.

Because these peptides influence growth hormone pathways, individual responses may vary.

Long-term safety data is limited. Ongoing monitoring and provider follow-up are recommended.

If you experience unusual symptoms (such as persistent swelling, numbness, or severe discomfort), discontinue use and contact your provider.

Do not use medication that appears compromised or improperly stored.

Do not share this medication or use it outside of medical supervision.

ACTIVE INGREDIENT:

This medication contains the following active ingredients. Do not use if you are allergic to any listed components.

  • CJC-1295
  • Ipamorelin

ALLERGIES:

Allergic reactions are uncommon but possible.

Stop this medication and seek medical care if you experience:

  • Rash or hives
  • Swelling of the face, lips, or throat
  • Difficulty breathing
  • Severe injection site reaction

CONDITIONS:

We evaluate your health history based on the information you provide. If any of the following apply or develop during treatment, discontinue use and seek in-person evaluation:

  • Known hypersensitivity to peptide therapies
  • Active infection at injection site
  • Unexplained swelling or neurological symptoms
  • Pregnancy or breastfeeding (safety not established)
  • History of hormone-sensitive conditions
  • Significant underlying medical conditions without provider clearance 

ACCURATE INFORMATION:

We evaluate the specific health information you provide and make our recommendations based on it. If you incorrectly provide that information, we may misdiagnose or fail to diagnose conditions that you may have which could affect our recommendation for treatment.

ACCEPTING OR DECLINING OUR RECOMMENDATION:

We recommend this treatment because the potential benefits of treatment outweigh the risks. You should evaluate this information as well as the manufacturer’s pamphlet, and any input from your in-person healthcare team, or other information to decide if this treatment plan is appropriate for you. You are free to decline our treatment recommendations although, doing so may prolong symptoms and be associated with negative outcomes.

OTHER TREATMENTS:

We have based our recommendation on your specific case and medical guidelines, but there may be alternative treatments or strategies that may be helpful to you. Some may be more or less effective than what we provide. Some treatments may require an in-person exam or procedure which we can’t provide.

SHARE WITH YOUR IN-PERSON HEALTHCARE TEAM:

You can access your records anytime. We strongly recommend that you update your in-person doctor, pharmacist, and the rest of your healthcare team to let them know about any new medicines you are taking or other changes in your health.